Veeva Systems Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended January 31, 2023; comparisons are with the fiscal year ended January 31, 2022. Veeva provides cloud software, data, analytics, and services, primarily to the life sciences industry.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Total revenue | $2.155 billion | $1.851 billion | +16% |
| Subscription revenue | $1.733 billion | $1.484 billion | +17% |
| Professional services and other revenue | $422 million | $367 million | +15% |
| Gross profit / margin | $1.546 billion / 72% | $1.347 billion / 73% | Profit +15%; margin down 1 point |
| Operating income | $459 million | $505 million | −9% |
| Net income | $488 million | $427 million | +14% |
| Diluted EPS | $3.00 | $2.63 | +14% |
| Cash provided by operations | $780 million | $764 million | +2% |
- Subscription services were 80% of revenue. Commercial Solutions accounted for 52% of total revenue and R&D Solutions 48%; R&D subscription revenue grew faster and represented an increasing share of the business.
- Operating expenses rose 29% to $1.087 billion, including a 36% increase in R&D spending. Stock-based compensation increased to $352 million from $235 million.
- Cash, cash equivalents, and short-term investments totaled approximately $3.1 billion at year-end: $886 million in cash and $2.216 billion in short-term investments. The filing presents no borrowings; lease liabilities totaled $61 million.
- Investing activities used $1.008 billion, largely reflecting increased net purchases of investments. Deferred revenue was $869 million, versus $732 million a year earlier.
- The effective tax rate fell to 4.2% from 16.6%, primarily due to stock-based compensation tax benefits. FY2023 included $94 million of excess tax benefits; the lower reported tax burden substantially supported net income growth.
Material changes and outlook
- Revenue growth slowed from 26% in FY2022 to 16% in FY2023; subscription growth likewise slowed from 26% to 17%. Management expects both growth rates to decline again in FY2024.
- Management expects FY2024 gross and operating margins to decrease. Factors include customer termination-for-convenience rights added to master agreements for multi-year orders beginning February 1, 2023, higher operating expenses, and increased stock-based compensation. The contract change is expected to reduce FY2024 revenue; from FY2025, recognized revenue on affected orders is generally expected to align with amounts invoiced.
- Management expects operating cash flow to be reduced by approximately $90 million in FY2024 if the tax-law requirement to capitalize and amortize research and development costs remains in effect.
- Veeva plans to move CRM applications from Salesforce’s platform to its own Vault platform: early adopters are targeted for 2024, broader availability for 2025, and existing customers must migrate by September 1, 2030. Veeva does not intend to renew its Salesforce agreement when it expires in September 2025.
- The company introduced an annual inflation adjustment for new or renewed orders after April 1, 2023, capped at the lower of 4% or the specified CPI measure; management does not expect a significant FY2024 revenue impact.
Risks, contingencies, and other notable items
- Key risks include CRM platform migration and customer retention, competition, cybersecurity and service availability, reliance on third-party infrastructure and data providers, life sciences industry spending and consolidation, foreign exchange, and the ability to attract and retain employees.
- Ongoing litigation includes IQVIA disputes involving trade-secret and antitrust claims, a Medidata appeal following a trial ruling in Veeva’s favor, and a Mednet matter scheduled for trial in early 2024. The filing says outcomes and potential losses cannot be estimated meaningfully. Veeva and Sparta Systems settled their claims against each other in February 2023.
- Customer concentration is notable: the top 10 customers generated 29% of revenue, down from 31%. No individual customer exceeded 10% of annual revenue.
- Available-for-sale investments had $31 million of gross unrealized losses at year-end; the company reported no other-than-temporary impairment. A 100-basis-point interest-rate increase was estimated to reduce portfolio market value by $24 million.
- Veeva is a public benefit corporation, and its board must balance stockholder financial interests with stakeholder interests and its stated public benefit purpose. Its dual-class voting structure was scheduled to end October 15, 2023.
- KPMG issued an unqualified opinion on the financial statements and concluded internal control over financial reporting was effective as of January 31, 2023. The auditor identified revenue audit evidence as a critical audit matter.
Important facts for investors to verify
- Track FY2024 revenue and subscription growth against management’s expectation of slower growth, including the accounting effect of new multi-year contract terms.
- Monitor CRM migration milestones, customer adoption, migration costs, and any churn or service disruption.
- Assess whether expense growth, stock-based compensation, and professional-services costs pressure margins as forecast.
- Review the sustainability of the unusually low FY2023 effective tax rate and the cash-flow effects of R&D tax amortization rules.
- Follow developments and financial exposure in the IQVIA, Medidata, and Mednet litigation, as potential losses are not clearly quantified in the filing.